"Statements suggesting AI is inherently better informed than physicians, or that physicians cannot be trusted to make ...

Cemdisiran, an investigational small interfering RNA (siRNA) therapeutic targeting complement component 5 (C5), led to fewer ...

An investigational dual GIP/GLP-1 agonist achieved modest weight loss in adults with type 2 diabetes and obesity, the phase ...

Starting a GLP-1 receptor agonist after giving birth is becoming more common, an analysis of claims data showed. The ...

Gastroenterologist Joseph Salhab, DO, shared his top ten natural laxatives to aid with regular bowel movements. Meanwhile, ...

A woman on death row in Tennessee survived two doses of lethal injection before her execution was called off. (The Hill) ...

Three Republican states went to the Supreme Court on Wednesday to challenge abortion "shield laws" protecting providers in ...

Users of GLP-1 receptor agonists had as much as fourfold higher likelihood for nail disorders, particularly onycholysis (separation of the fingernails or toenails), compared with patients not taking ...

The FDA expanded its approval of mavacamten (Camzyos) to include children with symptomatic obstructive hypertrophic ...

Adults with type 2 diabetes achieved impressive weight loss with an investigational combination agent of eloralintide plus ...

Alpha-gal syndrome, however, would be a risk: "It has been shown that unfed larval lone star ticks carry the protein that can cause alpha-gal in people," Oliver said, adding that the prevalence of the ...

Intravenous efgartigimod (Vyvgart) continued to demonstrate efficacy and safety in patients with generalized myasthenia gravis who did not have detectable anti-acetylcholine receptor (AChR) antibodies ...